Literature DB >> 15075167

Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China.

Rebecca J Garten1, Shenghan Lai, Jinbing Zhang, Wei Liu, Jie Chen, David Vlahov, Xiao-Fang Yu.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) is quickly spread through injection drug use. The prevalence and incidence of HCV in Chinese heroin users has been rarely reported.
METHODS: A longitudinal cohort of young injection drug users (IDU) from southern China was established to study the risk factors for blood-borne infections (597 subjects). Individuals underwent analysis for the presence of hepatitis B surface antigen and antibodies to human immunodeficiency virus type 1 (HIV-1), HCV and hepatitis B surface antigen. Using self-reported risk behaviours, multivariate regression analysis was performed for factors associated with HCV prevalence and seroconversion.
RESULTS: At baseline, HIV-1 and HCV prevalence was 17% and 72%, respectively. Significant factors associated with HCV seroprevalence included age >25 years (odds ratio [OR] = 1.71) and injection drug use for >2 years (OR = 2.60). HCV prevalence within one year of starting heroin use was 57% for any route of administration, and 80% if restricted to injectors. After two 6-month follow-up visits, 56 out of 159 baseline HCV seronegative individuals (148.9 total person years [py]), underwent seroconversion at an incidence rate of 37.6 per 100 py. Individuals who reported injection drug use were more likely to undergo HCV seroconversion (rate ratio [RR] = 6.59).
CONCLUSIONS: HCV infection is rapidly acquired in heroin users who adopt injection in southern China. This study emphasizes the urgent need to implement and expand injection prevention and primary substance abuse prevention programmes in China.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15075167     DOI: 10.1093/ije/dyh019

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  66 in total

1.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

Review 2.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 3.  Hepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implication.

Authors:  Vo Duy Thong; Srunthron Akkarathamrongsin; Kittiyod Poovorawan; Pisit Tangkijvanich; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 4.  Non-injection drug use and Hepatitis C Virus: a systematic review.

Authors:  Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss
Journal:  Drug Alcohol Depend       Date:  2006-12-15       Impact factor: 4.492

5.  Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals.

Authors:  Nora T Oliver; Christine M Hartman; Jennifer R Kramer; Elizabeth Y Chiao
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

6.  Prevalence and correlates of hepatitis C virus infection among street-recruited injection drug users in San Juan, Puerto Rico.

Authors:  Juan C Reyes; Héctor M Colón; Rafael R Robles; Eddy Rios; Tomás D Matos; Juan Negrón; Carmen Amalia Marrero; José M Calderón; Elizabeth Shepard
Journal:  J Urban Health       Date:  2006-11       Impact factor: 3.671

7.  Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review.

Authors:  P De; E Roy; J-F Boivin; J Cox; C Morissette
Journal:  J Viral Hepat       Date:  2008-01-20       Impact factor: 3.728

8.  High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China.

Authors:  Hong Shang; Ping Zhong; Jing Liu; Xiaoxu Han; Di Dai; Min Zhang; Ke Zhao; Rongzhen Xu; Xiao-Fang Yu
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

9.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

10.  Injection drug use is a risk factor for HCV infection in urban Egypt.

Authors:  Adela Paez Jimenez; Mostafa K Mohamed; Noha Sharaf Eldin; Hasnaa Abou Seif; Said El Aidi; Yehia Sultan; Nasr Elsaid; Claire Rekacewicz; Mostafa El-Hoseiny; May El-Daly; Mohamed Abdel-Hamid; Arnaud Fontanet
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.